🔎 Trials Near Me

Почетна › Hronična limfocitna leukemija › Kalifornija

Kliničke studije za Hronična limfocitna leukemija u državi Kalifornija

34 studija za Hronična limfocitna leukemija traži učesnike na lokacijama u državi Kalifornija.

Gradovi u državi Kalifornija

Zvanični tekst studije (na engleskom)

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  • GC2202 Study Site 115, Huntington Park
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05645107

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Kaiser Permanente-Anaheim, Anaheim
  • Kaiser Permanente-Baldwin Park, Baldwin Park
  • Kaiser Permanente-Bellflower, Bellflower
  • и још 28
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04269902

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  • UCLA Department of Medicine Hematologyoncology, Los Angeles
  • Scripps Prebys Cancer Center, San Diego
  • Pih Health Whittier Hospital, Whittier
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06846671

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • City of Hope Medical Center, Duarte
  • City of Hope at Irvine Lennar, Irvine
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT07582159

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

  • MemorialCare Health System - Long Beach Medical Center ( Site 5421), Long Beach
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT05947851

HPC Offered for PRESERVE Expansion

  • City of Hope, Duarte
Тражи се учесникОпсервациона студија
Узраст од 12 до 80 · Оба пола · Ажурирано 6. 11. 2026. · NCT07145411

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • City of Hope National Medical Center, Duarte
  • City of Hope National Medical Center, Irvine
  • Palo Alto Medical Foundation Research Institute (PAMFRI), Palo Alto
  • и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06588478

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
  • PCR Oncology, Arroyo Grande
  • AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
  • и још 22
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  • Kaiser Permanente-Anaheim, Anaheim
  • Kaiser Permanente-Baldwin Park, Baldwin Park
  • Kaiser Permanente-Bellflower, Bellflower
  • и још 29
Тражи се учесникФаза 3
Узраст 65 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07321652

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • City of Hope, Duarte
  • Cedars-Sinai Medical Center, Los Angeles
  • Scripps Health, San Diego
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07221500

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  • San Francisco VA Medical Center, San Francisco, CA, San Francisco
Тражи се учесникФаза 2
Узраст од 18 до 80 · Оба пола · Ажурирано 30. 10. 2026. · NCT06520098

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • City of Hope, Duarte
  • Valkyrie Clinical Trials, Los Angeles
Тражи се учесникФаза 1/2
Узраст од 13 до 90 · Оба пола · Ажурирано 26. 10. 2026. · NCT06533579

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

  • University of California, San Francisco, San Francisco
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT04545762

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

  • City of Hope Medical Center, Duarte
Тражи се учесникФаза 2Здраве особе су добродошле
Узраст од 18 до 75 · Оба пола · Ажурирано 23. 10. 2026. · NCT06059391

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  • Uci Health Laguna Hills, Laguna Hills
  • Chao Family Comprehensive Cancer Center, Orange
  • Stanford Cancer Institute, Palo Alto
  • и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT06943872

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

  • City of Hope Medical Center, Duarte
Тражи се учесникФаза 1Здраве особе су добродошле
Узраст од 18 до 75 · Оба пола · Ажурирано 23. 10. 2026. · NCT07020533

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  • City of Hope, Duarte
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT06528301

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • UC Irvine, Orange
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07648264

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  • Moores Cancer Center ( Site 0003), La Jolla
  • Care Access - South Pasadena ( Site 0070), Pasadena
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06136559

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

  • City of Hope Comprehensive Cancer Center, Duarte
  • City of Hope at Irvine Lennar, Irvine
  • University of California Davis Comprehensive Cancer Center, Sacramento
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT07061951

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
  • Stanford Medicine, Palo Alto
  • UCLA Santa Monica Cancer Care, Santa Monica
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT05006716

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

  • Research Site, La Jolla
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT06542250

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  • City of Hope National Medical Center, Duarte
  • Chao Family Comprehensive Cancer Center, Orange
  • Stanford Cancer Institute, Palo Alto
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT07277231

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • Kaiser Permanente Southern California, Irvine
  • University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
  • Cancer and Blood Specialty Clinic, Los Alamitos
  • и још 8
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT06973187

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • City of Hope National Medical Center, Duarte
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT04588922

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  • Pacific Cancer Medical Center, Inc, Anaheim
  • TOI Clinical Research, Cerritos
  • Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT05254743

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • City of Hope, Duarte
  • University of California, San Francisco, San Francisco
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 7. 2026. · NCT05131022

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  • City of Hope Medical Center, Duarte
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 4. 2026. · NCT06859008

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • City of Hope, Duarte
  • Los Angeles Cancer Network, Los Angeles
  • UCLA Medical Center of Hematology/Oncology, Los Angeles
  • и још 1
Тражи се учесникФаза 1/2
Узраст од 12 до 95 · Оба пола · Ажурирано 15. 4. 2026. · NCT04329728

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  • UCSF FRESNO/Community Cancer Institute /ID# 270874, Clovis
  • Valkyrie Clinical Trials /ID# 268151, Los Angeles
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 4. 2026. · NCT06428019

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • City of Hope, Duarte
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 3. 2026. · NCT04830137

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

  • City of Hope Medical Center, Duarte
  • City of Hope at Irvine Lennar, Irvine
  • City of Hope at Long Beach Elm, Long Beach
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 3. 2026. · NCT07218510

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

  • Moores Cancer Center at UC San Diego /ID# 230157, La Jolla
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 2. 2026. · NCT04895436

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • UC Irvine Health, Orange
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 12. 2025. · NCT05602363

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.